Zohreh Hojati

Prof. Zohreh Hojati

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Chemistry & Biology
Verified
Journal Article
Closed access
ZHZohreh Hojati
Zohreh Hojati
CMClaire Milne
Claire Milne
BHBarbara Harvey
Barbara Harvey
LGLyndsey Gordon
Lyndsey Gordon
MBMatthew Borg
Matthew Borg
JMJason Micklefield
Jason Micklefield

3 February 2015 in Jundishapur Journal of Microbiology
Verified
Journal Article
Open access
PDF file
ZHZohreh Hojati
Zohreh Hojati
RMRazieh Molaie
Razieh Molaie
AGAbolfazl Gholipour
Abolfazl Gholipour
BZBehnam Zamanzad
Behnam Zamanzad
MHMorteza Hashemzadeh
Morteza Hashemzadeh
Background: Urinary tract infections (UTIs) are one of main health problems caused by many microorganisms, including uropathogenic Escherichia coli (UPEC). UPEC strains are the most frequent pathogens responsible for 85% and 50% of community and hospital acquired UTIs, respectively. UPEC strains have special virulence factors, including type 1 fimbriae, which can result in worsening of UTIs. Objectives: This study was performed to detect type 1 fimbriae (the FimH gene) among UPEC strains by molecular method. Materials and Methods: A total of 140 isolated E. coli strains from patients with UTI were identified using biochemical tests and then evaluated for the FimH gene by polymerase chain reaction (PCR) analysis. Results: The UPEC isolates were identified using biochemical tests and were screened by PCR. The fimH gene was amplified using specific primers and showed a band about 164 bp. The FimH gene was found in 130 isolates (92.8%) of the UPEC strains. Of 130 isolates positive for the FimH gene, 62 (47.7%) and 68 (52.3%) belonged to hospitalized patients and outpatients, respectively. Conclusions: The results of this study indicated that more than 90% of E. coli isolates harbored the FimH gene. The high binding ability of FimH could result in the increased pathogenicity of E. coli; thus, FimH could be used as a possible diagnostic marker and/or vaccine candidate. Keywords: Urinary Tract Infections; Uropathogenic Escherichia Coli; FimH

EKElahe Kamali
Elahe Kamali
FRFatemeh Rahbarizadeh
Fatemeh Rahbarizadeh
ZHZohreh Hojati
Zohreh Hojati
MFMorten Frödin
Morten Frödin
Background: The ability of CRISPR/Cas9 to mutate any desired genomic locus is being increasingly explored in the emerging area of cancer immunotherapy. In this respect, current efforts are mostly focused on the use of autologous (i.e. patient-derived) T cells. The autologous approach, however, has drawbacks in terms of manufacturing time, cost, feasibility and scalability that can affect therapeutic outcome or wider clinical application. The use of allogeneic T cells from healthy donors may overcome these limitations. For this strategy to work, the endogenous T cell receptor (TCR) needs to be knocked out in order to reduce off-tumor, graft-versus-host-disease (GvHD). Furthermore, CD52 may be knocked out in the donor T cells, since this leaves them resistant to the commonly used anti-CD52 monoclonal antibody lymphodepletion regimen aiming to suppress rejection of the infused T cells by the recipient. Despite the great prospect, genetic manipulation of human T cells remains challenging, in particular how to deliver the engineering reagents: virus-mediated delivery entails the inherent risk of altering cancer gene expression by the genomically integrated CRISPR/Cas9. This is avoided by delivery of CRISPR/Cas9 as ribonucleoproteins, which, however, are fragile and technically demanding to produce. Electroporation of CRISPR/Cas9 expression plasmids would bypass the above issues, as this approach is simple, the reagents are robust and easily produced and delivery is transient.Results: Here, we tested knockout of either TCR or CD52 in human primary T cells, using electroporation of CRISPR/Cas9 plasmids. After validating the CRISPR/Cas9 constructs in human 293 T cells by Tracking of Indels by Decomposition (TIDE) and Indel Detection by Amplicon Analysis (IDAA) on-target genomic analysis, we evaluated their efficacy in primary T cells. Four days after electroporation with the constructs, genomic analysis revealed a knockout rate of 12–14% for the two genes, which translated into 7–8% of cells showing complete loss of surface expression of TCR and CD52 proteins, as determined by flow cytometry analysis.Conclusion: Our results demonstrate that genomic knockout by electroporation of plasmids encoding CRISPR/Cas9 is technically feasible in human primary T cells, albeit at low efficiency.

22 February 2017 in Journal of Genetics
Verified
Journal Article
Closed access
PDF file
SSSamira Sadeghi
Samira Sadeghi
ZHZohreh Hojati
Zohreh Hojati
HTHossein Tabatabaeian
Hossein Tabatabaeian

1 April 2019 in Archives of Medical Research
Verified
Journal Article
Closed access
MMMahzad Mostahfezian
Mahzad Mostahfezian
ZAZahra Azhir
Zahra Azhir
FDFariba Dehghanian
Fariba Dehghanian
ZHZohreh Hojati
Zohreh Hojati

7 September 2018 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ZAZahra Azhir
Zahra Azhir
FDFariba Dehghanian
Fariba Dehghanian
ZHZohreh Hojati
Zohreh Hojati